logo
Plus   Neg
Share
Email

Evotec Forms Breakpoint Therapeutics

Evotec SE (EVTCY.PK) said that it formed Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec's DNA damage response or "DDR" portfolio.

Breakpoint Therapeutics, which aims to accelerate early projects through discovery and pre-clinical development and expect to deliver the first IND-ready drug in 2022, will initially focus on advancing multiple drug discovery programmes initiated at Evotec that address high unmet medical needs of different patient groups.

The early stage funding amounting to 30 million euros will be covered by a consortium led by Medicxi, Taiho Ventures LLC, and Evotec. Evotec will hold below 50% of the company and consolidate at equity accordingly.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
RELATED NEWS
Follow RTT